RECRUITINGOBSERVATIONAL
Myval Global Study of Myval™ THV Series Implanted in Patients With Native Severe Aortic Valve Stenosis.
A Retrospective, Multinational, Multicentre, Observational Study in Patients Presenting With Native Severe Aortic Valve Stenosis and Treated With Myval™ Transcatheter Heart Valve Series in Real-world Setting.
About This Trial
A retrospective, multinational, multicentre, observational study in patients presenting with native severe aortic valve stenosis and treated with Myval™ Transcatheter Heart Valve Series in real-world setting.
Who May Be Eligible (Plain English)
Who May Qualify:
- All patients of this study must have received Myval™ THV series for treatment of native severe aortic stenosis and completed a minimum of 30-day follow-up.
Who Should NOT Join This Trial:
- No
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* All patients of this study must have received Myval™ THV series for treatment of native severe aortic stenosis and completed a minimum of 30-day follow-up.
Exclusion Criteria:
* No
Treatments Being Tested
DEVICE
Myval Transcatheter Heart Valve Series
Myval™ THV is a newer-generation balloon-expandable THV characterized by a nickel-cobalt alloy frame composed of a single element - hexagon arranged in a hybrid honeycomb fashion.
Locations (8)
North Estonia Medical center
Tallinn, Estonia
Clinical Institute Saint Ambrogio
Milan, Italy
Amphia Ziekenhui
Breda, North Brabant, Netherlands
University of Gdansk
Gdansk, Bażyńskiego, Poland
University Medical Centre Ljubljana
Ljubljana, Slovenia
Hospital Universitario de Gran Canaria Dr. Negrin
Las Palmas de Gran Canaria, Spain
Hospital Cliinico Univertistario de Valladolid
Valladolid, Spain
Kocaeli University School of Medicine
Kocaeli, Turkey (Türkiye)